Abstract
Purpose: To systematically review the value of serum inflammatory markers to diagnose diabetic foot osteomyelitis (DFO). Study selection: Studies to diagnose DFO using biomarkers erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin (PCT), interleukins (IL-2, IL-6, IL-8) and tumor necrosis factor alfa (TNF) were retrieved from EMBASE and PubMed with no language restrictions through July 2014. Data extraction: We summarized clinical characteristics of the studies and used bivariate random effects models and summary receiver operating characteristic curves to estimate sensitivity and specificity for each marker. Data synthesis: A total of 8 qualifying studies were included in our meta-analysis. Bivariate pooled sensitivity and specificity of the 6 studies examining ESR were 0.81 (95% CI 0.71-0.88) and 0.90 (95% CI 0.75-0.96) respectively. Due to the paucity of data, models did not converge for the other biomarkers. Conclusions: From the inflammatory markers, ESR appears to be the best laboratory test to identify patients with DFO.
Keywords: Diabetic foot, osteomyelitis, biomarkers, diabetic foot infection, diagnosis, erythrocyte sedimentation rate, c-reactive protein, procalcitonin.
Current Diabetes Reviews
Title:The Role of Biomarkers to Diagnose Diabetic Foot Osteomyelitis. A Meta-analysis
Volume: 12 Issue: 4
Author(s): Suzanne Aura Victoria van Asten, Edgar Joseph Geradus Peters, Yin Xi and Lawrence Alfred Lavery
Affiliation:
Keywords: Diabetic foot, osteomyelitis, biomarkers, diabetic foot infection, diagnosis, erythrocyte sedimentation rate, c-reactive protein, procalcitonin.
Abstract: Purpose: To systematically review the value of serum inflammatory markers to diagnose diabetic foot osteomyelitis (DFO). Study selection: Studies to diagnose DFO using biomarkers erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin (PCT), interleukins (IL-2, IL-6, IL-8) and tumor necrosis factor alfa (TNF) were retrieved from EMBASE and PubMed with no language restrictions through July 2014. Data extraction: We summarized clinical characteristics of the studies and used bivariate random effects models and summary receiver operating characteristic curves to estimate sensitivity and specificity for each marker. Data synthesis: A total of 8 qualifying studies were included in our meta-analysis. Bivariate pooled sensitivity and specificity of the 6 studies examining ESR were 0.81 (95% CI 0.71-0.88) and 0.90 (95% CI 0.75-0.96) respectively. Due to the paucity of data, models did not converge for the other biomarkers. Conclusions: From the inflammatory markers, ESR appears to be the best laboratory test to identify patients with DFO.
Export Options
About this article
Cite this article as:
Victoria van Asten Aura Suzanne, Geradus Peters Joseph Edgar, Xi Yin and Lavery Alfred Lawrence, The Role of Biomarkers to Diagnose Diabetic Foot Osteomyelitis. A Meta-analysis, Current Diabetes Reviews 2016; 12 (4) . https://dx.doi.org/10.2174/1573399811666150713104401
DOI https://dx.doi.org/10.2174/1573399811666150713104401 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Infective Strategies of the Future: Is there Room for Species-Specific Antibacterial Agents?
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy Neurobrucellosis: A Case Report with an Unusual Presentation
Recent Advances in Anti-Infective Drug Discovery Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews Vaccination and Antiviral Treatment of Neglected Diseases Caused by Flaviviral Infections
Current Medicinal Chemistry Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Adverse Effects and Drug Interactions of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition
Current Gene Therapy CD44 and its Role in Inflammation and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
Coronaviruses Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy Aquaporins and Neurodegenerative Diseases
Current Neuropharmacology Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine